Global Pravastatin Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pravastatin Market Insights, Forecast to 2034
Pravastatin (marketed as Pravachol or Selektine) is a member of the drug class of statins, used in combination with diet, exercise, and weight loss for lowering cholesterol and preventing cardiovascular disease.
Global Pravastatin market is expected to reach to US$ 582 million in 2024, with a positive growth of %, compared with US$ 547 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Pravastatin industry is evaluated to reach US$ 835 million in 2029. The CAGR will be 6.2% during 2024 to 2029.
Globally, Pravastatin key manufacturers include Bristol-Myers Squibb, TEVA, SANDOZ, APOTEX, Dr. Reddy's Laboratories, Zydus Pharmaceuticals, Cipla Inc., Lupin Pharmaceuticals and Glenmark, etc. Bristol-Myers Squibb, TEVA, SANDOZ are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Pravastatin were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Pravastatin market and estimated to attract more attentions from industry insiders and investors.
Pravastatin can be divided into 10mg Tablet, 20mg Tablet, 40mg Tablet and 80mg Tablet, etc. 10mg Tablet is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Pravastatin is widely used in various fields, such as Adults and Children, etc. Adults provides greatest supports to the Pravastatin industry development. In 2022, global % sales of Pravastatin went into Adults filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Pravastatin market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Pravastatin market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report

Bristol-Myers Squibb
TEVA
SANDOZ
APOTEX
Dr. Reddy's Laboratories
Zydus Pharmaceuticals
Cipla Inc.
Lupin Pharmaceuticals
Glenmark
Mylan
Aurobindo Pharma
Accord Healthcare
Upsher-Smith Laboratories
Hisun
Jiangxi Boyaseehot Pharmaceutical
Shanghai Shyndec Pharmaceutical
Daiichi Sankyo
North China Pharmaceutical Group
Segment by Type
10mg Tablet
20mg Tablet
40mg Tablet
80mg Tablet
Adults
Children
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Pravastatin plant distribution, commercial date of Pravastatin, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Pravastatin introduction, etc. Pravastatin Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Pravastatin
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Pravastatin market is expected to reach to US$ 582 million in 2024, with a positive growth of %, compared with US$ 547 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Pravastatin industry is evaluated to reach US$ 835 million in 2029. The CAGR will be 6.2% during 2024 to 2029.
Globally, Pravastatin key manufacturers include Bristol-Myers Squibb, TEVA, SANDOZ, APOTEX, Dr. Reddy's Laboratories, Zydus Pharmaceuticals, Cipla Inc., Lupin Pharmaceuticals and Glenmark, etc. Bristol-Myers Squibb, TEVA, SANDOZ are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Pravastatin were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Pravastatin market and estimated to attract more attentions from industry insiders and investors.
Pravastatin can be divided into 10mg Tablet, 20mg Tablet, 40mg Tablet and 80mg Tablet, etc. 10mg Tablet is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Pravastatin is widely used in various fields, such as Adults and Children, etc. Adults provides greatest supports to the Pravastatin industry development. In 2022, global % sales of Pravastatin went into Adults filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Pravastatin market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Pravastatin market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report

By Company
Bristol-Myers Squibb
TEVA
SANDOZ
APOTEX
Dr. Reddy's Laboratories
Zydus Pharmaceuticals
Cipla Inc.
Lupin Pharmaceuticals
Glenmark
Mylan
Aurobindo Pharma
Accord Healthcare
Upsher-Smith Laboratories
Hisun
Jiangxi Boyaseehot Pharmaceutical
Shanghai Shyndec Pharmaceutical
Daiichi Sankyo
North China Pharmaceutical Group
Segment by Type
10mg Tablet
20mg Tablet
40mg Tablet
80mg Tablet
Segment by Application
Adults
Children
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Pravastatin plant distribution, commercial date of Pravastatin, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Pravastatin introduction, etc. Pravastatin Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Pravastatin
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
